blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3300483

EP3300483 - ORAL SOLID FORMULATION CONTAINING IRINOTECAN AND METHOD OF PREPARING THE SAME [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.09.2023
Database last updated on 15.06.2024
FormerThe patent has been granted
Status updated on  07.10.2022
FormerGrant of patent is intended
Status updated on  29.05.2022
FormerExamination is in progress
Status updated on  11.06.2021
FormerRequest for examination was made
Status updated on  02.03.2018
FormerThe international publication has been made
Status updated on  06.01.2017
Most recent event   Tooltip10.05.2024Lapse of the patent in a contracting state
New state(s): BE, CH		published on 12.06.2024  [2024/24]
Applicant(s)For all designated states
Hanmi Pharm. Co., Ltd.
214 Muha-ro
Paltan-myeon
Hwaseong-si, Gyeonggi-do 18536 / KR
[2022/45]
Former [2018/14]For all designated states
Hanmi Pharm. Co., Ltd.
214 Muha-ro
Paltan-myeon
Hwaseong-si, Gyeonggi-do 18536 / KR
Inventor(s)01 / PARK, Caleb Hyung Min
802-905
49 Soman-ro
Deogyang-gu
Goyang-si Gyeonggi-do 10529 / KR
02 / JUNG, Myeong Ki
117-1101
30 Hwayang-ro 50beon-gil
Paldal-gu
Suwon-si Gyeonggi-do 16438 / KR
03 / KIM, Jin Cheul
501-1303
16 Dangsan-ro 42-gil
Yeongdeungpo-gu
Seoul 07216 / KR
04 / KIM, Yong Il
732-504
52 Jeongja-ro 42beon-gil
Jangan-gu
Suwon-si Gyeonggi-do 16325 / KR
05 / PARK, Jae Hyun
311-404
460 Yeongtong-ro
Yeongtong-gu
Suwon-si Gyeonggi-do 16707 / KR
06 / WOO, Jong Soo
120-2303
85 Hwasan-ro
Jangan-gu
Suwon-si Gyeonggi-do 16420 / KR
 [2018/14]
Representative(s)Marks & Clerk LLP
15 Fetter Lane
London EC4A 1BW / GB
[N/P]
Former [2022/45]Marks & Clerk (Luxembourg) LLP
44, rue de la Vallée
1017 Luxembourg / LU
Former [2018/14]Brevalex
95, rue d'Amsterdam
75378 Paris Cedex 8 / FR
Application number, filing date16818153.520.06.2016
[2018/14]
WO2016KR06513
Priority number, dateKR2015009341330.06.2015         Original published format: KR 20150093413
[2018/14]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017003120
Date:05.01.2017
Language:EN
[2017/01]
Type: A1 Application with search report 
No.:EP3300483
Date:04.04.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 05.01.2017 takes the place of the publication of the European patent application.
[2018/14]
Type: B1 Patent specification 
No.:EP3300483
Date:09.11.2022
Language:EN
[2022/45]
Search report(s)International search report - published on:KR05.01.2017
(Supplementary) European search report - dispatched on:EP09.11.2018
ClassificationIPC:A61K9/20, A61K31/4745, A61P35/00
[2018/50]
CPC:
A61K31/4745 (EP,CN,IL,KR,RU,US); A61K47/12 (IL,KR,RU,US); A61K47/20 (IL,US);
A61K9/16 (IL,RU); A61K9/1617 (CN,IL,KR,US); A61K9/1682 (IL,US);
A61K9/20 (IL,RU); A61K9/2013 (EP,CN,IL,KR,US); A61K9/2018 (EP,IL,US);
A61K9/2027 (EP,IL,US); A61K9/2054 (EP,IL,US); A61K9/48 (IL,RU);
A61K9/4858 (CN,IL,KR,US); A61P35/00 (EP,IL,US); A61K2300/00 (IL,US) (-)
Former IPC [2018/14]A61K47/12, A61K9/16, A61K9/20, A61K9/48, A61K31/4745
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/14]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:ORALE FESTE FORMULIERUNG MIT IRINOTECAN UND VERFAHREN ZUR HERSTELLUNG DAVON[2018/14]
English:ORAL SOLID FORMULATION CONTAINING IRINOTECAN AND METHOD OF PREPARING THE SAME[2018/14]
French:FORMULATION ORALE SOLIDE CONTENANT DE L'IRINOTÉCAN ET PROCÉDÉ DE PRÉPARATION DE CELUI-CI[2018/14]
Entry into regional phase26.12.2017National basic fee paid 
26.12.2017Search fee paid 
26.12.2017Designation fee(s) paid 
26.12.2017Examination fee paid 
Examination procedure26.12.2017Examination requested  [2018/14]
26.12.2017Date on which the examining division has become responsible
09.05.2019Amendment by applicant (claims and/or description)
14.06.2021Despatch of a communication from the examining division (Time limit: M03)
15.09.2021Reply to a communication from the examining division
30.05.2022Communication of intention to grant the patent
03.10.2022Fee for grant paid
03.10.2022Fee for publishing/printing paid
03.10.2022Receipt of the translation of the claim(s)
Opposition(s)10.08.2023No opposition filed within time limit [2023/42]
Fees paidRenewal fee
28.05.2018Renewal fee patent year 03
25.06.2019Renewal fee patent year 04
25.06.2020Renewal fee patent year 05
23.06.2021Renewal fee patent year 06
02.06.2022Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL09.11.2022
AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
MC09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SI09.11.2022
SK09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
IE20.06.2023
LU20.06.2023
BE30.06.2023
CH30.06.2023
[2024/24]
Former [2024/21]AL09.11.2022
AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
MC09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SI09.11.2022
SK09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
IE20.06.2023
LU20.06.2023
Former [2024/15]AL09.11.2022
AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
MC09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SI09.11.2022
SK09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
LU20.06.2023
Former [2024/09]AL09.11.2022
AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
MC09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SI09.11.2022
SK09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
Former [2023/51]AL09.11.2022
AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SI09.11.2022
SK09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
Former [2023/38]AL09.11.2022
AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SK09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
Former [2023/37]AL09.11.2022
AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
Former [2023/35]AT09.11.2022
CZ09.11.2022
DK09.11.2022
EE09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
NL09.11.2022
PL09.11.2022
RO09.11.2022
RS09.11.2022
SE09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
Former [2023/34]AT09.11.2022
DK09.11.2022
EE09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
NL09.11.2022
PL09.11.2022
RS09.11.2022
SE09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
Former [2023/33]AT09.11.2022
DK09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
NL09.11.2022
PL09.11.2022
RS09.11.2022
SE09.11.2022
SM09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
Former [2023/29]AT09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
NL09.11.2022
PL09.11.2022
RS09.11.2022
SE09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
Former [2023/26]AT09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
PL09.11.2022
RS09.11.2022
SE09.11.2022
NO09.02.2023
GR10.02.2023
IS09.03.2023
PT09.03.2023
Former [2023/24]AT09.11.2022
FI09.11.2022
HR09.11.2022
LT09.11.2022
LV09.11.2022
SE09.11.2022
NO09.02.2023
GR10.02.2023
PT09.03.2023
Former [2023/23]AT09.11.2022
FI09.11.2022
LT09.11.2022
LV09.11.2022
SE09.11.2022
NO09.02.2023
GR10.02.2023
PT09.03.2023
Former [2023/22]AT09.11.2022
FI09.11.2022
LT09.11.2022
SE09.11.2022
NO09.02.2023
PT09.03.2023
Former [2023/20]LT09.11.2022
NO09.02.2023
Documents cited:Search[XI]US6881420  (FLASHNER-BARAK MOSHE [IL], et al) [X] 1,6-11 * Claims, in particular claims 4, 8, 12-25; Description, in particular col 6, 8-15, 17-19 and examples 5-6, in particular formulations 20, 21, 22. *[I] 2-4,12-14;
 [A]US2007299099  (SHIMIZU HIDEAKI [JP], et al) [A] 1-14 * claims, description and table 1 *;
 [ID]WO2010015688  (BIOALLIANCE PHARMA [FR], et al) [ID] 1-14 * Claims and description, in particular pages 4-5, 11-12, 18-19 and examples. *;
 [XPI]WO2015107131  (ONCORAL PHARMA APS [DK]) [XP] 1-3,5-14 * Claims, desciption (in particular of vehicle on page 8 last paragraph and of additional components on pages 10-11). Especially composition of P01 and P07. * [I] 4;
 [A]  - MACHIDA Y ET AL, "EFFICACY OF NANOPARTICLES CONTAINING IRINOTECAN PREPARED USING POLY(DL-LACTIC ACID) AND POLY(ETHYLENE GLYCOL)-POLY(PROPYLENE GLYCOL)-POLY(ETHYLENE GLYCOL) AGAINST M5076 TUMOR IN THE EARLY LIVER METASTATIC STAGE", SCIENCES TECHNIQUES ET PRATIQUES - STP PHARMA SCIEN, ED. DE SANTÉ, FR, (20030101), vol. 13, no. 4, ISSN 1157-1489, pages 225 - 230, XP008038371 [A] 1-14 * whole document, in particular paragraph I.3 *
International search[A]WO03074527  (PHARMACIA ITALIA SPA [IT], et al) [A] 1-14 * See the whole document. *;
 [A]US6881420  (FLASHNER-BARAK MOSHE [IL], et al) [A] 1-14 * See the whole document. *;
 [A]US2006030578  (AHMAD IMRAN [US], et al) [A] 1-14 * See the whole document. *;
 [X]US2007299099  (SHIMIZU HIDEAKI [JP], et al) [X] 1-14 * See abstract; paragraphs [0026], [0031], [0038], [0045]-[0046], [0062]; claims 1-10; and table 1. *;
 [A]WO2014085371  (GLAXOSMITHKLINE LLC [US]) [A] 1-14* See the whole document. *
by applicantWO0130351
 US6881420
 EP2328557
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.